KLRK1 and neoplasm: Comparing T cell gene expression between treatments revealed a significant increase in Klrk1, Klrc2, Klrd1, Fasl, and Sema4a in CD4 T cells at the tumor site after HVJ-E/OX40 antibody injection (Figures 7A and S7).